VCNX News and Press, Vaccinex Inc. From 08/14/23

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) ...

ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President ...

2023-05-15 17:32:24 ET Vaccinex press release ( NASDAQ: VCNX ): Q1 GAAP EPS of -$0.10. Revenue of $0.55M. For further details see: Vaccinex GAAP EPS of -$0.10, revenue of $0.55M

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneeri...

Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated ...

GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New technology makes it possible to present GPCR and ion channels i...

2023-04-03 08:58:27 ET Vaccinex ( NASDAQ: VCNX ) closed the private placement of 4.98M shares at a purchase price of $0.41/share for gross proceeds of $2.04M. Net proceeds from the private placement to be used for funding the ongoing development and clinical trials of its...

2023-04-03 08:40:11 ET Vaccinex press release ( NASDAQ: VCNX ): FY GAAP EPS of -$0.47. Revenue of $0.28M (-68.9% Y/Y). For further details see: Vaccinex GAAP EPS of -$0.47, revenue of $0.28M

ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4...

Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for a pre-planned interim analysis of KEYNOTE B84 phase 1b/2 study in Head and Neck Squam...